Fundraising FoxStemina Biomarker Discovery
Madison, US · Founded 2014 · Delaware corporation
Find your way into Stemina Biomarker Discovery
Sign up to see every warm intro you have to Stemina Biomarker Discovery
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Stemina Biomarker Discovery team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Stemina Biomarker Discovery develops in vitro assays using human stem cell-derived cells to predict drug toxicity and support drug discovery and development. The company serves pharmaceutical and biotech firms seeking developmental and cardiac safety screening.
Founders & leadership
Stemina Biomarker Discovery was founded in 2014 by Elizabeth Donley and Gabriela Cezar.
Board
Reported raises · per SEC filings
Form D private placements$5.3M disclosed across 2 rounds · 2014–2016
▶$4.3MraisedJun 2016 · 29 investors · BiotechnologyRule 506(b)
- Andrew FerraraDirector
- R. Andrew MorganDirector
- Scott CarrDirector
- Kevin KrenitskyDirector
- Elizabeth L.R. DonleyExecutive Officer, Director
- Robert E. BurrierExecutive Officer
- Marc SchneebaumDirector
- Offering amount
- $7.1M
- Amount sold
- $4.3M
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1MraisedJun 2016 · 1 investors · BiotechnologyRule 506(b)
- Elizabeth L.R. DonleyExecutive Officer, Director
- Scott CarrDirector
- Marc SchneebaumDirector
- Andrew FerraraDirector
- R. Andrew MorganDirector
- Kevin KrenitskyDirector
- Robert BurrierExecutive Officer
- Offering amount
- $1.1M
- Amount sold
- $1M
- First sale
- May 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Stemina Biomarker Discovery.
Non-dilutive funding · 7 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $2.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $146.7K |
| National Science Foundation | Phase II | 2011 | $500K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2010 | $999.9K |
| National Science Foundation | Phase I | 2009 | $149.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $149.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Stemina Biomarker Discovery do?
- Stemina Biomarker Discovery develops in vitro assays using human stem cell-derived cells to predict drug toxicity and support drug discovery and development. The company serves pharmaceutical and biotech firms seeking developmental and cardiac safety screening.
- Who founded Stemina Biomarker Discovery?
- Stemina Biomarker Discovery was founded by Elizabeth Donley, Gabriela Cezar in 2014.
- How much funding has Stemina Biomarker Discovery raised?
- Stemina Biomarker Discovery has disclosed $5.3M raised across 2 rounds.
- Where is Stemina Biomarker Discovery headquartered?
- Stemina Biomarker Discovery is headquartered in Madison, US.